Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

Blood loss after cardiac surgery can be caused by impaired platelet (PLT) function after cardiopulmonary bypass.

Desmopressin or 1-deamino-8-D-arginine vasopressin (DDAVP) is a synthetic analog of vasopressin.

Who Took Part

The study group was 102 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

A total of 102 patients undergoing valvular heart surgery (from October 2010 to June 2011) were divided into DDAVP group (n = 52) and control group (n = 50).

At the same time, an equal volume of saline was given to the patients in the control group.

How the Study Was Run

The design is described as randomized.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

PLT aggregation rate was measured with the AggRAM four-way PLT aggregation measurement instrument.

The blood loss and transfusion, hemoglobin levels, PLT counts, and urine outputs at different time were recorded and compared.

What Was Measured

In this study, the researchers assessed the effects of DDAVP on PLT aggregation and blood loss in patients undergoing cardiac surgery.

The subject headings attached to it are Cardiac Surgical Procedures, Deamino Arginine Vasopressin, Hemorrhage and Platelet Aggregation.

What This Means in Plain Language

The paper is a randomized study of Vasopressin and Desmopressin in 102 patients.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Chinese medical journal), a journal based in China.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.